Image

Barbara Feder Ostrov

Articles

<p>Here’s what we’re reading today:</p> <p>Journalists’ Pfriend? Gary Schwitzer and Andrew Holtz weigh in on <a href="http://www.healthnewsreview.org/blog/2010/09/pfizer---a-pfriend-of-jour…’s sponsorship of a National Press Foundation education program about Alzheimer's</a>, a disease for which Pfizer makes medications.</p> <p>Medical Loss Ratios: If you’re wondering what these are, check out <a href="http://www.gooznews.com/node/3449">Merrill Goozner’s analysi</a>s of some recent proposed regulations on this key element of health reform.</p>

<p>Here’s what we’re reading today:</p> <p><strong>Avandia:</strong> Fortune’s Shelly Dubois analyzes why the FDA <a href="http://money.cnn.com/2010/09/24/news/companies/FDA_Avandia_GSK_ban.fort…;“maimed” the diabetes drug Avandia</a> but didn’t permanently pull it off the market, as its European Union counterpart did. Quote of the day: “Avandia lives on in these United States as a zombie shell of its former top blockbuster self.”</p>